1. Home
  2. AKTX vs AERT Comparison

AKTX vs AERT Comparison

Compare AKTX & AERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • AERT
  • Stock Information
  • Founded
  • AKTX N/A
  • AERT 2012
  • Country
  • AKTX United States
  • AERT Singapore
  • Employees
  • AKTX N/A
  • AERT N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • AERT Professional Services
  • Sector
  • AKTX Health Care
  • AERT Consumer Discretionary
  • Exchange
  • AKTX Nasdaq
  • AERT Nasdaq
  • Market Cap
  • AKTX 41.8M
  • AERT 38.3M
  • IPO Year
  • AKTX N/A
  • AERT N/A
  • Fundamental
  • Price
  • AKTX $1.16
  • AERT $1.18
  • Analyst Decision
  • AKTX
  • AERT
  • Analyst Count
  • AKTX 0
  • AERT 0
  • Target Price
  • AKTX N/A
  • AERT N/A
  • AVG Volume (30 Days)
  • AKTX 28.0K
  • AERT 315.5K
  • Earning Date
  • AKTX 08-18-2025
  • AERT 08-14-2025
  • Dividend Yield
  • AKTX N/A
  • AERT N/A
  • EPS Growth
  • AKTX N/A
  • AERT N/A
  • EPS
  • AKTX N/A
  • AERT 0.47
  • Revenue
  • AKTX N/A
  • AERT $70,851,000.00
  • Revenue This Year
  • AKTX N/A
  • AERT N/A
  • Revenue Next Year
  • AKTX N/A
  • AERT N/A
  • P/E Ratio
  • AKTX N/A
  • AERT $2.59
  • Revenue Growth
  • AKTX N/A
  • AERT 4.38
  • 52 Week Low
  • AKTX $0.85
  • AERT $0.46
  • 52 Week High
  • AKTX $4.40
  • AERT $2.93
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 44.02
  • AERT 71.55
  • Support Level
  • AKTX $1.15
  • AERT $1.03
  • Resistance Level
  • AKTX $1.22
  • AERT $1.33
  • Average True Range (ATR)
  • AKTX 0.07
  • AERT 0.20
  • MACD
  • AKTX 0.00
  • AERT 0.02
  • Stochastic Oscillator
  • AKTX 36.53
  • AERT 70.86

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About AERT Aeries Technology Inc.

Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.

Share on Social Networks: